Literature DB >> 16274329

Risperidone in pervasive developmental disorders.

Craig A Erickson1, Kimberly A Stigler, David J Posey, Christopher J McDougle.   

Abstract

Atypical antipsychotics are increasingly used in the treatment of severe behavioral disturbances in people with pervasive developmental disorders. Among these compounds, risperidone has been the most broadly studied. This drug profile will review the available data on the use of risperidone in individuals with pervasive developmental disorders. In addition, the chemistry, pharmacokinetics, pharmacodynamics and metabolism of risperidone are discussed. Emphasis will be placed on adverse effects associated with risperidone in these people, including a discussion of measures that can be taken to monitor for these effects. Finally, a discussion of the future direction of risperidone use in this population and key issues will be presented.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16274329     DOI: 10.1586/14737175.5.6.713

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  7 in total

1.  Effects of risperidone on dopamine receptor subtypes in developing rat brain.

Authors:  Taylor Moran-Gates; Christopher Grady; Young Shik Park; Ross J Baldessarini; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2006-12-18       Impact factor: 4.600

2.  Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats.

Authors:  Yong Kee Choi; Taylor Moran-Gates; Matthew P Gardner; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2009-10-29       Impact factor: 4.600

3.  Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6-17 years.

Authors:  Kelly Blankenship; Craig A Erickson; Kimberly A Stigler; David J Posey; Christopher J McDougle
Journal:  Ped Health       Date:  2010-09-29

4.  A prospective open-label study of aripiprazole in fragile X syndrome.

Authors:  Craig A Erickson; Kimberly A Stigler; Logan K Wink; Jennifer E Mullett; Arlene Kohn; David J Posey; Christopher J McDougle
Journal:  Psychopharmacology (Berl)       Date:  2011-02-12       Impact factor: 4.530

5.  Effects of risperidone on glutamate receptor subtypes in developing rat brain.

Authors:  Yong Kee Choi; Matthew P Gardner; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2008-10-09       Impact factor: 4.600

6.  Pharmacologic Interventions for Irritability, Aggression, Agitation and Self-Injurious Behavior in Fragile X Syndrome: An Initial Cross-Sectional Analysis.

Authors:  Eleanor M Eckert; Kelli C Dominick; Ernest V Pedapati; Logan K Wink; Rebecca C Shaffer; Howard Andrews; Tse-Hwei Choo; Chen Chen; Walter E Kaufmann; Nicole Tartaglia; Elizabeth M Berry-Kravis; Craig A Erickson
Journal:  J Autism Dev Disord       Date:  2019-11

7.  Gene expression in blood is associated with risperidone response in children with autism spectrum disorders.

Authors:  L Lit; F R Sharp; K Bertoglio; B Stamova; B P Ander; A D Sossong; R L Hendren
Journal:  Pharmacogenomics J       Date:  2011-06-07       Impact factor: 3.550

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.